These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 15970491)
1. Cardenolide and bufadienolide ligands of the sodium pump. How they work together in NaCl sensitive hypertension. Bagrov AY; Fedorova OV Front Biosci; 2005 Sep; 10():2250-6. PubMed ID: 15970491 [TBL] [Abstract][Full Text] [Related]
2. Brain ouabain stimulates peripheral marinobufagenin via angiotensin II signalling in NaCl-loaded Dahl-S rats. Fedorova OV; Agalakova NI; Talan MI; Lakatta EG; Bagrov AY J Hypertens; 2005 Aug; 23(8):1515-23. PubMed ID: 16003178 [TBL] [Abstract][Full Text] [Related]
3. Endogenous ligand of alpha(1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride--dependent hypertension. Fedorova OV; Talan MI; Agalakova NI; Lakatta EG; Bagrov AY Circulation; 2002 Mar; 105(9):1122-7. PubMed ID: 11877366 [TBL] [Abstract][Full Text] [Related]
9. Endogenous cardiac glycosides: hormones using the sodium pump as signal transducer. Schoner W; Scheiner-Bobis G Semin Nephrol; 2005 Sep; 25(5):343-51. PubMed ID: 16139690 [TBL] [Abstract][Full Text] [Related]
10. Endogenous and exogenous cardiac glycosides and their mechanisms of action. Schoner W; Scheiner-Bobis G Am J Cardiovasc Drugs; 2007; 7(3):173-89. PubMed ID: 17610345 [TBL] [Abstract][Full Text] [Related]
11. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Schoner W; Scheiner-Bobis G Am J Physiol Cell Physiol; 2007 Aug; 293(2):C509-36. PubMed ID: 17494630 [TBL] [Abstract][Full Text] [Related]
12. Endogenous cardiotonic steroids and differential patterns of sodium pump inhibition in NaCl-loaded salt-sensitive and normotensive rats. Bagrov AY; Agalakova NI; Kashkin VA; Fedorova OV Am J Hypertens; 2009 May; 22(5):559-63. PubMed ID: 19229192 [TBL] [Abstract][Full Text] [Related]
13. Coordinated shifts in Na/K-ATPase isoforms and their endogenous ligands during cardiac hypertrophy and failure in NaCl-sensitive hypertension. Fedorova OV; Talan MI; Agalakova NI; Lakatta EG; Bagrov AY J Hypertens; 2004 Feb; 22(2):389-97. PubMed ID: 15076199 [TBL] [Abstract][Full Text] [Related]
14. Synthesis of an Endogenous Steroidal Na Pump Inhibitor Marinobufagenin, Implicated in Human Cardiovascular Diseases, Is Initiated by CYP27A1 via Bile Acid Pathway. Fedorova OV; Zernetkina VI; Shilova VY; Grigorova YN; Juhasz O; Wei W; Marshall CA; Lakatta EG; Bagrov AY Circ Cardiovasc Genet; 2015 Oct; 8(5):736-45. PubMed ID: 26374826 [TBL] [Abstract][Full Text] [Related]
16. Marinobufagenin, an endogenous inhibitor of alpha-1 Na/K-ATPase, is a novel factor in pathogenesis of diabetes mellitus. Bagrov YY; Manusova NB; Egorova IA; Frolova EV; Fedorova OV; Bagrov AY Dokl Biol Sci; 2005; 404():333-7. PubMed ID: 16405108 [No Abstract] [Full Text] [Related]
17. The central role of the brain in salt-sensitive hypertension. Huang BS; Amin MS; Leenen FH Curr Opin Cardiol; 2006 Jul; 21(4):295-304. PubMed ID: 16755197 [TBL] [Abstract][Full Text] [Related]
18. Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension. Fedorova OV; Talan MI; Agalakova NI; Droy-Lefaix MT; Lakatta EG; Bagrov AY Hypertension; 2003 Mar; 41(3):505-11. PubMed ID: 12623951 [TBL] [Abstract][Full Text] [Related]
19. Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives. Anderson DE; Fedorova OV; Morrell CH; Longo DL; Kashkin VA; Metzler JD; Bagrov AY; Lakatta EG Am J Physiol Regul Integr Comp Physiol; 2008 Apr; 294(4):R1248-54. PubMed ID: 18287222 [TBL] [Abstract][Full Text] [Related]
20. Involvement of Na(+), K(+)-ATPase and endogenous digitalis-like compounds in depressive disorders. Goldstein I; Levy T; Galili D; Ovadia H; Yirmiya R; Rosen H; Lichtstein D Biol Psychiatry; 2006 Sep; 60(5):491-9. PubMed ID: 16712803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]